1073-65-0

Basic information

• Product Name: 4-Pyrimidinecarboxaldehyde, oxime (7CI,8CI,9CI)
• Synonyms: 4-Pyrimidinecarboxaldehyde, oxime (7CI,8CI,9CI);4-Pyrimidinecarboxaldehyde oxime;PyriMidine-4-carbaldehyde oxiMe
• CAS NO: 1073-65-0
• Molecular Formula: C5H5N3O
• Molecular Weight: 123.1127
• Product Categories: PYRIMIDINE
• Mol File: 1073-65-0.mol
• Article Data: 2

Chemical Properties

• Melting Point: 153-154℃
• Boiling Point: 251℃
• Flash Point: 106℃
• Appearance: /
• Density: 1.28
• Vapor Pressure: 1.23mmHg at 25°C
• Refractive Index: 1.607
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Pyrimidinecarboxaldehyde, oxime (7CI,8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyrimidinecarboxaldehyde, oxime (7CI,8CI,9CI)(1073-65-0)
• EPA Substance Registry System: 4-Pyrimidinecarboxaldehyde, oxime (7CI,8CI,9CI)(1073-65-0)

Safety Data

• Hazardous Substances Data: 1073-65-0(Hazardous Substances Data)

Usage

General Description

4-Pyrimidinecarboxaldehyde, oxime is a compound with the chemical formula C5H5N3O, commonly referred to as 4-Pyrimidinecarboxaldehyde, oxime (7CI,8CI,9CI). This chemical is an aldehyde oxime derivative of pyrimidine, with a molecular weight of 127.111 g/mol. It is commonly used in organic synthesis and as a reagent in chemical reactions. 4-Pyrimidinecarboxaldehyde, oxime (7CI,8CI,9CI) has potential applications in the pharmaceutical and agrochemical industries, as well as in the field of material science. Its structure and properties make it useful for the development and synthesis of various compounds and materials.

InChI:InChI=1/C5H5N3O/c9-8-3-5-1-2-6-4-7-5/h1-4H,(H,6,7)/b5-3-

Upstream product

• 3438-46-8 4-Methylpyrimidine 

Downstream Products

• 618446-08-5 C-pyrimidin-4-yl-methylamine dihydrogen chloride 
• 42839-04-3 Pyrimidine-4-carbonitrile 
• 39870-05-8 4-acetyl pyrimidine 

Relevant articles and documents

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.